Agilon 医疗
AGL
85.12
-3.33
-3.76%
Agilon 医疗
US · AGL
#3034 按市值排名
上市于 2021
85.12
-3.33
-3.76%
实时 - 追踪5344个代码 - 心跳于14秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例上升了0.3个百分点。
机构持股
- 机构持股比例
- 97.37% +0.29pp
- 机构数量
- 219 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund38.15%
Hedge Fund26.47%
VC/PE Fund24.45%
Public Company4.55%
Individual/Insider2.25%
Private Company2.11%
Family Office/Trust0.75%
Insurance Company0.62%
Government Pension Fund0.26%
Other0.39%
主要股东 截至 2026-06-30
Clayton, Dubilier & Rice, LLC
23.82% · 4.00M 股
Morgan Stanley Investment Management Inc.
11.71% · 1.97M 股
North Peak Capital Management, LLC
8.84% · 1.49M 股
BlackRock
6.83% · 1.15M 股
AQR Capital Management
4.02% · 674.66K 股
Vanguard Capital Management, LLC
3.65% · 613.63K 股
The Goldman Sachs Group, Inc.
3.61% · 605.84K 股
Marshall Wace LLP
2.79% · 468.29K 股
Durable Capital Partners, LP
2.62% · 440.64K 股
D. E. Shaw & Co., L.P.
2.32% · 390.15K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 25次买入 · 25次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Clayton, Dubilier & Rice, LLC | -- | 23.82% |
| Ronald Williams | Chairperson | 0.88% |
| Denise Zamore | Chief Legal Officer | 0.39% |
| Sharad Mansukani | Independent Director | 0.32% |
| Benjamin Shaker | Chief Markets Officer | 0.22% |
| Jeffrey Schwaneke | Independent Director | 0.11% |
| John Wulf | Director | 0.09% |
| Timothy Gertsch | Chief Accounting Officer | 0.08% |
| Karen McLoughlin | Independent Director | 0.04% |
| Silvana Battaglia | Independent Director | 0.03% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-15 | Timothy Gertsch | Chief Accounting Officer | Sale to Issuer | -17 | $96.90 |
| 2026-07-31 | Denise Zamore | Chief Legal Officer | Sale to Issuer | -37 | $91.61 |
| 2026-06-30 | Jeffrey Schwaneke | Independent Director | Sale to Issuer | -2,311 | $111.74 |
| 2026-06-01 | Ronald Williams | Chairperson | Other Acquisition | +2,133 | -- |
| 2026-06-01 | Sharad Mansukani | Independent Director | Other Acquisition | +2,133 | -- |
| 2026-06-01 | Silvana Battaglia | Independent Director | Other Acquisition | +2,133 | -- |
| 2026-06-01 | Diana McKenzie | Independent Director | Other Acquisition | +2,133 | -- |
| 2026-06-01 | Karen McLoughlin | Independent Director | Other Acquisition | +2,133 | -- |
| 2026-06-01 | John Wulf | Director | Other Acquisition | +2,133 | -- |
| 2026-05-31 | Denise Zamore | Chief Legal Officer | Sale to Issuer | -485 | $92.54 |
| 2026-05-23 | Timothy Gertsch | Chief Accounting Officer | Sale to Issuer | -8 | $86.39 |
| 2026-05-06 | Timothy O’Rourke | Chief Executive Officer | Other Acquisition | +120,000 | -- |
| 2026-05-06 | Timothy O’Rourke | Chief Executive Officer | Other Acquisition | +200,000 | -- |
| 2026-04-14 | Girish Venkatachaliah | Chief Technology Officer | Sale to Issuer | -426 | $22.68–26.88 |
| 2026-04-14 | Benjamin Shaker | Chief Markets Officer | Sale to Issuer | -675 | $22.68–26.88 |
| 2026-04-14 | Denise Zamore | Chief Legal Officer | Sale to Issuer | -240 | $22.68–26.88 |
| 2026-04-14 | Timothy Gertsch | Chief Accounting Officer | Sale to Issuer | -147 | $22.68–26.88 |
| 2026-03-31 | Jeffrey Schwaneke | Independent Director | Sale to Issuer | -1,662 | $9.75 |
| 2026-03-31 | Jeffrey Schwaneke | Independent Director | Other Acquisition | +75,000 | -- |
| 2026-03-31 | Girish Venkatachaliah | Chief Technology Officer | Sale to Issuer | -480 | $9.75 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Agilon 医疗 讨论区 0 条评论